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Abstract
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Non-small cell lung cancer (NSCLC) is the most frequent type of lung cancer accounting up to
80-85% of all lung cancer cases. Gemcitabine (Gem), a pyrimidine nucleoside antimetabolite, is
widely used chemotherapy offering several months survival benefit in patients with NSCLC. The
emergence of Gem resistance is a main clinical concern in cancer treatment and thus a continuous
demand for development of new therapeutic strategies to improve its antitumor activity. Hence, we
report an adjuvant therapeutic regimen based on natural compound, gambogic acid (GA) which
has been shown to enhanced Gem induced inhibition of cancer cell growth, arrest cell cycle,
induce apoptosis by enhanced accumulation of Gem. The in vitro cell viability, clonogenicity,
invasion, and migration assays demonstrate a significantly higher therapeutic effect of Gem when
it was combined with GA in A549 and H1299 cells. A better access of internalization of drug
molecules achieved in Rhodamine 123 assay when GA was used as adjuvant treatment. Further,
GA and Gem combination significantly reduced tubular formation of HUVEC cells indicates
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lowering angiogenesis potential. Microarray and western blot studies confirm that GA+Gem cotreatment strategy promotes cancer cell death by downregulating anti-apoptosis proteins,
chemoresistance-associated proteins, and upregulation of apoptosis proteins. More importantly, a
significant higher therapeutic benefit was noticed for GA and Gem combination in A549 xenograft
mice model. Together, these results offer a rationale to evaluate the clinical translational possibility
of GA as adjuvant therapy to overcome Gem resistance. This combination regimen can be a new
therapeutic concept to eradicate this devastating disease.

Graphical Abstract

Author Manuscript
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1.

Introduction

Author Manuscript

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting
for 80-85% of the LC cases (Siegel et al., 2018, 2020). Surgery, radiation, chemotherapy,
and immunotherapy are the current therapeutic options for NSCLC (Baker et al., 2016;
Baxevanos and Mountzios, 2018; Blakely and Jahan, 2011; Schrank et al., 2018; Zhao et al.,
2018). Chemotherapeutic agents, such as, cisplatin, docetaxel, gemcitabine (Gem),
irinotecan, paclitaxel, vinorelbine, etc., are the most effective therapeutic regimen for
NSCLC (Favaretto et al., 2009; Miller et al., 1995; Sweeney and Sandler, 1998). However,
these agents provide good initial response and offer slight increment in overall survival but
patients eventually will develop drug resistance (Formisano et al., 2018; Rotow and Bivona,
2017). As a result therapy needs increased drug dosage for effective treatment which offers
severe side effects (Chua et al., 2004; MacDonagh et al., 2016; Ramalingam and Belani,
2004; Sekine et al., 2004; Zhao et al., 2018). Thus, drug resistance is a major challenge for
NSCLC therapy.

Author Manuscript

Gem (2′,2′-difluorodeoxycytidine), a pyrimidine analogue of the nucleoside antimetabolite,
has been widely used in the treatment of NSCLC (Hayashi et al., 2011; Toschi and
Cappuzzo, 2009). Gem exerts its anti-tumor activity through its triphosphate metabolite
(dFdCTP) which arrests the DNA replication/synthesis and eventually precedes to apoptosis
(Huang and Plunkett, 1995). Gem can increase the objective response rate of patients by
20-25% (4-9 months) with relatively low toxicity profile (Hayashi et al., 2011). Gem
chemoresistance also hinders the maximum capacity of Gem therapeutic outcome (d’Amato
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et al., 2007). In 3,042 NSCLC patient tumor cohort, ~72% tumors found to be either extreme
or intermediate resistance against Gem (d’Amato et al., 2006). Intrinsic resistance is caused
by metabolic regulation of Gem uptake and other anti-apoptotic pathways (Achiwa et al.,
2004; Bergman et al., 2002).

Author Manuscript

Gambogic acid (GA, chemical formula; C38H44O8), a xanthonoid derived from the resin of
Garcinia hanburyi tree (Kale et al., 2018; Zhao et al., 2010). Previous reports have identified
GA as a potent apoptosis inducer, an anticancer agent, and inhibitor of tumor growth
(Kashyap et al., 2016). GA has shown to be potent molecule with very low half-maximal
inhibitory concentrations (IC50) (nM range) against cancer cell lines (Banik et al., 2018;
Zhu et al., 2009). GA has apoptotic effects on various cancer cells by modulating different
signaling pathway such as MAPK/ERK, PI3K/AKT, and NF-κB (Banik et al., 2018). GA
also show chemosensitization effects on various cancer types, by inhibiting P-glycoprotein
(P-gp) and suppressing survivin expression (Wang et al., 2015). GA alone and in
combination with various therapeutic agents show promising chemosensitization and
synergistic therapeutic benefits (Banik et al., 2018; Kashyap et al., 2016). Phase IIa clinical
trial was approved by Chinese Food and Drug Administration with GA as single agents for
lung cancer (Chi et al., 2013) and other solid tumors (Chi et al., 2013; Wang et al., 2014b).

Author Manuscript

In this study, we report an innovative combination strategy to induce elevated anticancer
effects which may ultimately reduce tumor burden of NSCLC. A chemotherapeutic agent
(gemcitabine) and natural compound (gambogic acid) (Fig. 1A) are composited at various
ratios in treatment regimen to achieve the synergistic effect of GA with Gem in in vitro
assays and in vivo. This superior effect was observed since GA sensitizes NSCLC tumor
cells to Gem therapy by inhibiting drug resistance phenomenon in cancer cells while
inducing higher apoptosis potential.

2.
2.1.

Materials and methods
Chemicals and regents
GA was purchased from Gaia Chemical Corporation (Gaylordsville, CT, USA) and
dissolved in in dimethyl sulfoxide (DMSO) and restored in −20 °C and diluted further for
usage, where DMSO was less than 0.1% in the final dilutions. Gem was purchased from
Fisher Scientific (Waltham, MA, USA) and dissolved in sterile 1X PBS. All the other
reagents, solvents, chemicals, and cell culture plastics were obtained from Fisher Scientific
(Pittsburgh, PA, USA) and Sigma–Aldrich Co. (St. Louis, MO, USA), unless otherwise
stated.

Author Manuscript

2.2.

Cell lines and culture conditions
BEAS-2B (ATCC® CRL-9609™, lung, bronchus epithelial virus transformed, normal
cells), HUV-EC-C [HUVEC] (ATCC® CRL-1730™, vascular endothelium normal cells),
A549 (ATCC® CCL-185™, about 22 hours, lung epithelial cells derived from lung
carcinomatous tissue from a 58-year-old, Caucasian male), and NCI-H1299 (ATCC®
CRL-5803™, lung epithelial derived from metastatic site lymph node; male 43 years adult,
Caucasian with non-small cell lung cancer) cells were obtained from American Type Culture
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Collection (ATCC, Manassas, VA, USA) and maintained as described earlier (Hatami et al.,
2018). A549 and H1299 cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) and Roswell Park Memorial Institute medium (RPMI-1640) (Gibco, Thermo
Fisher Scientific, Grand Island, NY, USA), while BEAS-2B and HUVEC cells were cultured
in bronchial epithelial cell growth medium (BEGM) and endothelial cell growth medium-2
(EGM™-2) (Lonza, Morristown, NJ, USA) contained 10% fetal bovine serum (FBS) and
1% (w/v) penicillin–streptomycin (Gibco, Thermo Fisher Scientific). These cell lines were
grown in humidified incubator at 37 °C with a 5% CO2 environment (Thermo Fisher
Scientific, Waltham, MA, USA). All cell lines were regularly monitored for their typical
morphology and contamination under the microscope. These cells in log-phase were
trypsinized and seeded for various in vitro studies.
2.3.

Cell viability assay

Author Manuscript
Author Manuscript

The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell growth assay
kit (#CT02, Sigma) was employed to determine cell viability following treatment with GA,
Gem, and the combination of GA and Gem in NSCLC cells. While the effect of GA and
Gem were also investigated in normal human lung bronchial epithelial cells (BEAS-2B). For
this study, cells (5×103) were seeded into 96-well sterile culture plates and left for overnight
to attach the plates. Cells were treated with varying concentrations of GA (25, 50, 100, 200,
and 400 nM) and Gem (25, 50, 100, and 200 nM) as well as the combination of both GA and
Gem for 48 h. Every treatment was performed in triplicate per experiment and each
experiment performed three times. After 48 h treatment, 20 μl of MTT solution (5 mg/ml)
was added to 100 μl of the culture medium in each well, and plates were incubated at 37 °C
for another for 3 h. The culture medium containing MTT solution was discarded and the
formed formazan crystals were dissolved in 100 μl DMSO solution in each well for 15 min
at room temperature (RT) under shaking. After this step, the absorbance was measured using
a microplate reader (Cytation™ 5, BioTek Instruments, Winooski, VT, USA) at 490 nm
according to the manufacturer’s instructions. The cell viability of treated cells was
normalized to absorbance readings in untreated control cells (considered to have 100%
viability). The IC50 calculation was performed using GraphPad Prism 6.07 software. The
IC50 was referred as the concentration required for 50% cell growth inhibition. The
combination index (CI) was calculated using the Chou–Talalay method (Zhao et al., 2017),
as presented below;
CI =

Dc1
Dc2
Dc1 Dc2
)
+
+(
Ds1
Ds2
Ds1 Ds2

Author Manuscript

Where Ds1 and Ds2 represent the IC50 of GA and Gem, respectively, while Dc1 and Dc2 are
the IC50 values of the drugs applied in combination. Combination index designated as: CI <
0.9, synergism, 0.9-1.1, additive effect, >1.1 antagonism, respectively.
2.4.

Colony formation
For this assay, A549 and H1299 cells (~300 cells/well) were seeded in 12-well sterile culture
plates. Cells were allowed 48 h to initiate colonies (3-4 cells per colony). Then cells were
treated with and without 25 and 50 nM GA, 25 and 50 nM Gem, and the combination of
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both drugs with respective concentrations. The drug-containing medium was renewed every
3 days, for 15 days. After 15 days of incubation, grown colonies were washed with 1X PBS,
fixed with pure cold methanol, and stained with 0.05% crystal violet at RT. Images of the
colonies were acquired using a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA,
USA) (Nagesh et al., 2018b). All colonies were counted electronically using the NIH ImageJ
software (www.imagej.nih.gov/ij/).
2.5.

Cell migration

Author Manuscript

Cell migration experiments were performed in Corning® Transwell® 96-well Boyden
chambers (8 μm) (#3374, Corning®, NY, USA) with each well separated by microporous
membrane (8 μm pores) as per manufacturer’s instructions (Chowdhury et al., 2019).
Briefly, starved cells (overnight starvation by culturing in serum-free medium) (5×104 cells/
well) were seeded in upper chambers of the plate containing serum-free culture medium.
These cells were exposed to 100 nM and 200 nM of GA; 100 nM and 200 nM of Gem; and
combination of GA and Gem drugs for 18 h, respectively. Cells without treatment served as
controls. Cells were allowed to migrate from upper chambers with serum free medium
towards lower chambers with complete medium containing 10% FBS. The migrated cells at
the lower side of the inserts were fixed with cold 4% paraformaldehyde for 30 min, rinsed
with 1X PBS, and stained with crystal violet for 45 min. Cells in the upper chamber were
completely removed using cotton swabs. The experiments were performed in triplicate and
three random fields were imaged from replicate wells using a Keyence BZ-X800 microscope
(Itasca, IL, USA). The number of migrated cells were quantified using ImageJ software.
2.6.

Cell invasion

Author Manuscript

The ability of cells to invade was evaluated using BioCoat Matrigel Invasion Chambers (BD
Biosciences, Bedford, MA, USA) (Chowdhury et al., 2019). After starvation, cells (3.5×104
cells/well) were seeded in the upper chamber of the trans-well plate, containing serum free
medium. Cells were left 24 h for adhesion. After 24 h, they were exposed to treatments with
(100 and 200 nM) GA, (100 nM and 200 nM) Gem, and combination of both drugs, for 24
h. Cells without treatment served as controls. Cells invaded to the lower chamber were fixed,
stained, and imaged and quantified as mentioned above. This experiment was done in
triplicate.
2.7.

P-gp function by Rhodamine 123 assay

Author Manuscript

To investigate the effect of GA to facilitate Gem higher accumulation inside the cells for its
potential activity, the P-gp function in cancer cells was determined by Rhodamine 123
(Rh123) accumulation (Chowdhury et al., 2019; Nagesh et al., 2018b). Higher accumulation
of Rh123 indicator for lower in P-gp function. For this study, A549 and H1299 cells (5×105
cells/well) were cultured in a 6-well plate and left overnight to adhere to the plate. The next
day, cells were treated with 100 and 200 nM GA, 100 nM Gem, and the combination
treatment. After 24 h of treatment, 2.62 mM Rh123 was added to each well and cells were
placed back into the CO2 incubator for 30 min. Cells were then rinsed twice with sterile 1X
PBS, in order to wash any undesirable Rh123 dye adhering to the cell surface. Next, the
medium was replaced with fresh phenol red-free medium and subjected to imaging using an
EVOS® FL Imaging System (AMF4300, Life Technologies, Carlsbad, CA, USA) for
Eur J Pharmacol. Author manuscript; available in PMC 2021 December 05.
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qualitative examination. After that, cells were trypsinized and collected in phenol red-free
medium which were subjected for quantitative evaluation of extent of Rh123 accumulation
by using the NovoCyte Flow Cytometer (ACEA NovoCyte® 1000, ACEA Biosciences, Inc.
San Diego, Ca, USA). An FITC channel (fluorescence measurements at λex: 485 nm and
λem: 520 nm) was used to measure the mean fluorescence intensity (MFI) of Rh123 dye
that was internalized in the cells.
2.8.

Cell cycle analysis

Author Manuscript

For the cell cycle analysis, A549 and H1299 cells (5×105 cells/well) were seeded into 6-well
plates for culture overnight. Cells were then treated with 100 and 200 nM GA, 200 nM Gem,
and the combination of GA and Gem for 24 h, respectively. These cells were washed with
1XPBS, trypsinized, and collected by centrifugation at 1000 g for 5 min and fixed with 70%
pure ethanol and kept at least for 48 h at −20 °C. Cells were washed with 1X PBS and
incubated with propidium iodide (PI) and FxCycle™PI/RNase Staining solutions at 37 °C
for 1 h in the dark following manufacturer’s instructions. Cell cycle analysis was followed
by using a Bio-Rad ZE5 FACS flow cytometer (Bio-Rad Laboratories, Hercules, CA, USA)
(Hafeez et al., 2017). Cell cycle distribution and the different cell cycle phase of cells were
analyzed by the ModFit software (Verity Software House, USA).
2.9.

Apoptosis detection

Author Manuscript

The dead cell apoptosis kit with Annexin V Alexa Fluor™ 488 and PI (Thermo Fisher
Scientific, Pittsburgh, PA, USA) was used to detect apoptosis by flow cytometer. For this
study, A549 and H1299 cells (5×105 cells/well) were plated in 6-well plates and cultured
overnight. The cells were incubation with 200 nM GA, 200 nM Gem, and 200 nM GA + 200
nM Gem separately for 48 h. These cells were harvested and washed twice in cold 1X PBS
and pelleted by centrifugation at 500 g for 10 min. Then resuspended 100 μl in 1X Annexinbinding buffer. Stained with 5 μl Alexa Fluor® 488 Annexin V reagent and 1 μl of 100
μg/ml PI, for each 100 μl of cell suspension and incubated in the dark for 15 min at RT
(Hafeez et al., 2017; Wang et al., 2015). They were then mixed gently with 400 μl of binding
buffer and kept on ice while immediately processing them with a Bio-Rad ZE5 FACS flow
cytometer.
2.10.

Western blotting

Author Manuscript

Protein extractions from A549 cells treated with 200 nM GA, 200 nM Gem, and 200 nM
GA+200 nM Gem combination were performed using standard protocols as previously
reported (Nagesh et al., 2018a). For the western blotting, equal amounts of cellular protein
(40 μg) were denatured in sample lysis buffer and subjected to 4-20% SDS–PAGE. Proteins
were transferred from gel to a nitrocellulose membrane using the trans-blot electrophoretic
transfer cell containing Tris-glycine buffer, pH 8.3, and methanol, the transfer procedure was
performed 0-4 °C for 150 min at 55 V (400 mA). For blocking purposes, 3% BSA was used
for 1 h at RT. Nitrocellulose membranes were probed with primary antibodies overnight
incubation at 4 °C on a rocker. The following primary antibodies, cleaved caspase 3 (#9665),
Cl-PARP (#5625), Bcl-2 (#2872), Bak (#3814), RRM2 (#65939) and β-Actin (#4970) (Cell
Signaling Technologies, Danvers, MA, USA) were used. Next, membranes were washed
three times with PBST (each time for 5 min) and incubated with respective secondary
Eur J Pharmacol. Author manuscript; available in PMC 2021 December 05.
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antibodies for 45 min. Finally, the blots were subjected to immunoreactive proteins on
nitrocellulose membrane using Bio-Rad ECL Western Blotting Substrate Solution (Bio-Rad
Laboratories, Hercules, CA, USA) (Nagesh et al., 2018a). Blots were imaged using a BioRad computer-based gel imaging instrument with ImageLab™ software (Bio-Rad
Laboratories, Hercules, CA, USA).
2.11.

Angiogenesis assay

Author Manuscript

For examining in vitro angiogenesis, the tube formation ability of HUVEC cells were
assessed in presence and absence of the treatments (Chen et al., 2003). HUVECs (1×104
cells/well) with passages number less than five, were seeded in pre-coated Matrigel flatbottomed 96-well plates (Corning, NY, USA). After incubation for 4 h with the medium
containing 200 nM GA, 200 nM Gem, and 200 nM GA + 200 nM Gem combination,
HUVEC tubular formation was evaluated by phase-contrast at 10X magnification and
photographed at 3 random fields by using the EVOS® FL Imaging System. The length of
tubules was analyzed inside 2×2 square area at the center of each well (Chen et al., 2003).
Each experiment was repeated in triplicate.
2.12.

Microarray analysis

Author Manuscript

The total mRNA from A548 cell line upon treatment with 200 nm GA, 200 nm Gem and
200+200 nm GA+Gem was extracted using RNA Isolation Kit (Qiagen, Inc., Hilden,
Germany). Quality and purification steps of mRNA were followed as reported earlier
(Nagesh et al., 2018a; Nagesh et al., 2019). The purified mRNA samples were subjected and
hybridized to gene microarray studies using Affymterix Clariom S Human gene array or
GeneChip® Human gene 2.0 ST array (Affymterix, Santa Clara, CA, USA). Each sample
was triplicated for mRNA expression profile. The obtained results were validated iPathway
guide analysis (Advaita Corporation, Plymouth, MI, USA) (Nguyen et al., 2016) and the
gene expression fold changes between the treatments and no treatment groups were resulted
from Impact Analysis (Draghici et al., 2003; Khatri et al., 2007).
2.13. In vivo anti-tumor effects of GA and Gem combination in A549 xenograft mice
model

Author Manuscript

For this pilot study, 12 athymic male nude mice (6-8-week-old) were supplied by Jackson
laboratory (Bar Harbor, ME USA) to generate subcutaneous A549 cell line derived
xenograft tumors. Mice were housed under specific pathogen-free condition in accordance
with the recommendation of the Association for Assessment and Accreditation of
Laboratory Animal Care guidelines. The experiments were performed by following a
protocol (#18-031.0) approved by Animal Use and Care Administrative Advisory
Committee at the University of Tennessee Health Science Center, Memphis, TN, USA. The
tumor xenografts were established by injecting 2×107 A549 cells per mouse in 100 μl
DMEM medium and Matrigel (Corning Inc., Corning, NY) in 1:1 ratio on the dorsal flank.
Mice allowed to develop tumors and tumor volumes were measured using a digital caliper
[tumor volumes, V = (0.5238 x L x W x H), where L, W, and H are length, width, and height
of the tumor, respectively]. Upon reaching tumor volumes ~ 100 mm3, mice were treated
intraperitoneally with (saline), GA (2 mg/kg mice), Gem (20 mg/kg mice), and GA+Gem
(2+20 mg/kg mice). Each time the administered dose was maintained in 50 μl total volume.
Eur J Pharmacol. Author manuscript; available in PMC 2021 December 05.
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These treatments were twice a week. We used less concentration of GA in this study because
higher concentration may lead to significant tumor growth reduction which may not offer to
see its chemosensitization potential. After treatments, tumors were excised and formalin
fixed and paraffin embedded for immunohistochemistry for testing proliferation potential
using PCNA marker (# 8109, Cell Signaling Technologies, Danvers, MA, USA). The extent
of immunostaining was viewed under Keyence microscope at 20X magnification.
2.14.

Statistical analysis

Author Manuscript

The GraphPad Prism (GraphPad Software, Inc, La Jolla, CA, USA) software was used for
statistical analysis. Data was presented as mean ± standard deviation. To compare the means
of pairs of groups, Studen’s t-test was applied, while to compare three or more groups a oneway ANOVA was used. *P < 0.05, **P < 0.01, and ***P < 0.001 was considered statistically
significant compared to control group and #P < 0.05 was considered statistically significant
compared to GA and Gem treatment groups.

3.
3.1.

Results
Combination of GA and Gem synergistically reduce the growth of NSCLC cells

Author Manuscript

The MTT assay showed that 25-400 nM of GA had no significant effect on cell viability of
lung cancer (A549 and H1299) (Fig. 1B) and lung epithelial (BEAS-2B) cell lines (Fig. 1C).
This confirmed useful concentrations that can be applied in combination therapies without
any toxicity on normal cells. GA can sensitize tumor cells to various chemotherapy agents.
Thus, the potential for synergy between GA and Gem was evaluated in two NSCLC cell
lines through proliferation assay. Gem (0-200 nM) showed dose dependent effects on cell
viability (Fig. 1D–E). This effect was significantly enhanced when combined with 25-400
nM of GA treatments. The IC50 of Gem was drastically reduced to 4.4, 2.2, and 0.63 nM
with 100, 200, and 400 nM GA treatments in A549 cell lines. It was also followed similar
trend observed in reduction of IC50 of Gem to 6.1, 3.6, and 1.2 nM with GA combination
treatment in H1299 cells. Such shifts in lowering of the dose–response effects were clearly
seen in Fig. 1D–E. This cell viability data was used to calculate the combination index (CI)
using the Chou–Talalay (CompuSyn) method. As displayed in (Fig. 1F), the combination of
GA and Gem showed a synergetic effect (CI < 1) in both A549 and H1299 cell lines.
Moreover, CI values obtained at higher concentration of GA were lower, indicating more of
a synergistic effect on cells.
3.2. GA plus Gem treatment promotes the suppression of colony formation, migration
and invasion ability of NSCLC cells

Author Manuscript

Clonogenic assay represents an in vitro quantitative technique to evaluate the ability of a
cancer cell to sprout into a larger colony formation by expansion of colonies. The clonogenic
potential is an indicator for undifferentiated cancer cells to grow into tumors. Thus, the
synergy of GA and Gem combination was tested using long-term colony formation assay
and colonies were stained by 0.05% crystal violet for visualization (Fig. 2A). Clones were
larger and more prevalent in control wells and the clone size and number of colonies were
reduced in the GA or Gem treated groups, later represented graphically (Fig. 2B). Whereas
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strong inhibitory colony formation was noticed with GA and Gem combination and this
effect was being synergistic compared with the single drugs and controls.
Migration characteristic of NSCLC cells is crucial for distant metastases. Cancer cell’s
ability to reorganize its cytoskeleton and movement is required for invasion. Cancer cells
which can’t migrate towards a source of nutrition and invade through an organ may not
survive. Therefore, the influence of this new treatment strategy was examined on both
migration and invasion properties of NSCLC cells (Fig. 3).

Author Manuscript

As shown in Fig. 3A and C, A549 and H1299 cells treated with Gem alone showed a
~50-20% migration and invasion compared to their untreated control groups. GA treatment
did not show any inhibitor effects on migration and invasion characteristics of cells. When
these cell lines were treated with GA+Gem combination strongly restrict their migration and
invasiveness. This reduction in migrated and invaded cell data analyzed by ImageJ software
was found to be a synergistic effect of combination treatment than that of control as well as
the GA and Gem alone treatment (*P < 0.05, **P < 0.01, and #P < 0.05 Fig. 3B and D) in
both cell lines.
3.3.

GA and Gem combination reduced P-gp activity in NSCLC cells

Author Manuscript

To learn possible reason of significant anticancer potential of GA and Gem combination
compared to GA or Gem treatments, a P-gp activity assay was applied. In general, less P-gp
expression offers more accumulation of drug(s) to act on cells. Rhodamine 123 is a
fluorescent dye and acts as P-gp substrate. Thus, it can be used as indicator to evaluate the
ability of drug efflux by P-gp transporters. To determine the effect of GA on inhibition of Pgp efflux activity, A549 and H1299 cells were exposed to GA and Gem (alone and in
combination). The higher accumulation of Rh123 in cells indicates lower in P-gp expression.
As shown in Fig. 4A, cells treated with GA showed higher fluorescence intensity due to
Rh123 accumulation in comparison with cells without GA treatment (Fig 4B). Intracellular
Rh123 accumulation in NSCLC cells was dose-dependent, as higher GA concentrations
showed higher Rh123 accumulation, while lower accumulation was observed with Gem
treatment. This may be due to the higher expression of P-gp, which suggest that GA has an
inhibitory effect on P-gp efflux activity that resulted in the higher fluoresce inside cells. This
result signifies the chemo sensitization ability of GA on NSCLC cells and shows that GA
prevents drug efflux from cancer cells by decreasing the function of P-gp.
3.4.

Combined GA and Gem treatment induces significant apoptosis in NSCLC cells

Author Manuscript

Analysis of the cell cycle revealed that GA arrested cells S and G2 phases while Gem
treatment arrested cells in S phase cycle. GA and Gem combination treatment related their
combined effect on cell cycle distribution (Fig. 5A). The percent of G2 phase arrest remains
almost similar around ~40% in both 100 and 200 nM GA treatments. This was observed
because the employed GA concentration for treatment was low. To achieve a significant
change in cell cycle analysis, at least 500 nm, 1, or 2 μM of GA need to be used (Xia et al.,
2017). The combination treatment significantly increased the apoptotic cell population in the
cell cycle process compared to treatment with either single agent, in both A549 and H1299
cells. A detailed cell cycle distribution was presented in Table 1.
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Apoptosis is truly differentiated from necrosis, or accidental cell death, by distinctive
morphological changes in conjunction with biochemical changes, as it is known well by
specific nuclear and cytoplasmic properties, and loss of membrane alignments and
asymmetry. The transference of phosphatidylserine protein (PS) to the outer surface of the
cell membrane is one of the primary features of apoptosis, thus in order to distinguish the
early or late apoptotic cells, the Annexin-V/PI double staining assay was employed.
Additionally, dual staining with PI allows differentiation of early apoptotic cells with
undisturbed membranes (positive Annexin V and negative PI) from late apoptotic/necrotic
cells with permeable membranes (positive Annexin V and positive PI) and normal cells
(negative Annexin V and negative PI). The Annexin-V-Alexa Fluor/PI dual staining assay
indicated that GA induced a decrease in the percentage of live cells (bottom left) with a
concomitant increase in the percentage of early apoptotic cells (upper left) and late apoptotic
cells (upper right) as compared to untreated cells, in a dose-dependent manner (Fig. 5B). GA
+Gem cotreatment significantly induced approximately 6% and 18% of early and late
apoptotic cells, respectively. A detailed quadrat cell population of this analysis is presented
in Table 2.

Author Manuscript

3.5.

Combination of GA and Gem inhibit tube formation in HUVEC cells

Author Manuscript

Angiogenesis is another important characteristic that is often linked to the development,
progression and drug resistance phenomenon in many cancers including NSCLC. The tube
formation assay mimics the in vivo angiogenesis condition that represents the cellular
growth in the form of capillary-like and branched networks on the surface of extracellular
matrix. Suppressing the angiogenesis and causing damage to the tumor vascular network,
leads to the inhibition of tumor growth by abducting supply of oxygen and nutrients. The
effect of GA and Gem, either as monotherapy or in combination, was assessed for their
ability to inhibit tube formation using a HUVEC line (Pingwara et al., 2017). GA+Gem
combination treatment led to significant decrease not only in tube network lengths but their
network junction and size than that of the GA or Gem treatments. This can be clearly viewed
in phase contrast images (Fig. 6A). Semi-quantitative analysis demonstrates that treatment
of 200 nM GA, 100 nM Gem, and their combination (200 nM GA, 100 nM Gem) reduced
the total master segments length by ~33, 71, and 97%, respectively, compared to the vehicle
control (Fig. 6B). Combining these two compounds achieved the highest inhibition
compared to single drugs and the difference was statistically significant.
3.6.

Synergistic mechanisms of GA+Gem in promoting apoptosis in NSCLC cells

Author Manuscript

The superior anticancer potential of this combination treatment was determined through
western blot analysis. The Bcl-2 expression was drastically reduced while Bak was induced
during combination than alone GA and Gem treatments. Additionally, the expression of clPARP and cl-caspase 3 was profoundly elevated during combinatorial treatments than GA
and Gem alone exposure (Fig. 7A). Also, we observed MDR and RRM2 expression was
decreased by synergistically by drug combination. Thus, the combination treatment was
effective over single drug treatment through synergistic mechanisms in A549 cells.
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3.7. Microarray analysis confirms potential synergistic action of GA and Gem
combination
Microarray analysis contributes to the expression of thousands of genes simultaneously in
cells. In fact, this precise gene expression data can establish a scoring system to predict
synergy of GA+Gem therapy in NSCLC. Apparently, the microarray data collectively
validated the in vitro functional assays and western blot studies. A detailed analysis
indicated that up-regulation of genes associated to apoptosis while down-regulation of genes
belongs to pro-survival, angiogenic, metastasis, and drug resistance associated, in GA+Gem
treated A549 cells compared to GA/Gem or vehicle treated cells. Fig. 7B–E summarizes
these results in the form of heat maps utilizing heatmapper software (University of Alberta,
Edmonton, AB, Canada). Altogether, microarray data confirms that GA+Gem combination
treatment indeed enhance Gem-induced anticancer activity in NSCLC cells via
downregulation of drug-resistance phenomenon while inducing excessive apoptosis features.

Author Manuscript

3.8. GA and Gem combination significantly reduce tumor burden in A549 xenograft
mouse model

Author Manuscript

Considering our in vitro results, we anticipate that Gem with a combination treatment of GA
may cause increased therapeutic activity in A549 NSCLC xenograft mouse model. Up on
reaching a volume of 100-150 mm3, mice were randomly assigned and treated with a
combination of GA and Gem. Since GA is used as a dietary supplement with
chemosensitization and anticancer activity, we proposed a low concentration as possible (2
mg/kg mice). Treatments were performed twice a week for 4-6 weeks and tumor growth was
measured using digital Vernier calipers. As anticipated, the pilot combination therapy (GA
+Gem) resulted in a significantly lower tumor growths in mice compared with
monotherapies (GA or Gem) and control mice (Fig. 8). A negligible tumor growth was
observed with combination treatment compared to their individual treatment (Fig 8B).
Interestingly, dissected tumors show visible blood vessels in control, GA, and Gem
treatment groups whereas it was significantly lower in GA+Gem combination treatment
(Fig. 8C). This suggest possible role in reducing angiogenesis with the combination
treatment. Altogether, GA+Gem combination therapy induce synergistic and superior antitumor benefit in NSCLC. To observe GA+Gem combination effect on tumor growth, a
PCNA was probed in IHC study (Fig. 8D). It clearly indicates that PCNA marker staining is
minimal in GA+Gem (~27%) combination while control (~95%), GA (~86%) and Gem
(~42%) treatments exhibits significant amount of PCNA staining.

4.

Discussion

Author Manuscript

Non-small cell lung cancer is the most commonly diagnosed (approximately 228,820) and
exhibiting a high annual mortality about 23% (72,500 cancer deaths) annually in the United
States (Siegel et al., 2020). NSCLC still incurable and treatments have aided to inhibit the
tumor growth that helps to prolong survival. Chemotherapy is considered as the promising
treatment option for patients with NSCLC, either alone or in combination with resection or
radiotherapy. Clinical treatment regiments often include platinum, cisplatin, doxorubicin, 5fluorouracil, paclitaxel, docetaxel, Gem, etc. for lung cancer (Lee, 2019). Gem is a
cornerstone and widely employed chemotherapeutic agent to improve survival of lung
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cancer patients with minimal known systemic toxicity over other chemotherapeutic agents.
Multiple studies advice that Gem treatment exhibited 16–38.5% response rate with 6.6–7.7
months overall survival. Therapeutic efficacy of Gem needs further improvement. Clinically,
Gem-related resistance often noticed as a prime impediment in lung cancer treatment. The
present study aimed to assess a clinically relevant chemo sensitization approach which can
potentiate Gem induced anticancer efficacy.

Author Manuscript

GA, a caged xanthone natural compound, is known for its potent anti-cancer and
chemosensitization properties. To date a couple of studies have already shown that the
anticancer effect of GA on NSCLC (Zhao et al., 2017). Collective literature evidence
demonstrates that GA in combination with adriamycin, cisplatin, doxorubicin, 5fluorouracil, and gefitinib, promotes therapeutic benefit via sensitizing cancer cells (Kale et
al., 2018). However, GA’s chemosensitization effect on Gem therapy in NSCLC has not
been examined. In this study, we investigate the role of GA as synergistic chemosensitizer to
potentiate Gem therapeutic efficacy and can result in reduced resistance and enhanced anticancer potential of Gem both in vitro (Fig. 1–7) and in vivo (Fig. 8).

Author Manuscript

Our study for the time reports an enhanced anticancer effect of GA+Gem combination on
NSCLC. The results of the cell viability assay reveled that cotreatment of GA and Gem on
A549 and H1299 inhibited proliferation in a dose-dependent manner (Fig 1). The
combination of GA and Gem resulted in synergistic growth inhibition of A549 and H1299
cells which is validated with the Chou–Talalay method (Fig. 1) (Wang et al., 2014a; Zhao et
al., 2017; Zhu et al., 2019). This was confirmed through combination indexes that were
lower than 0.9 (CI<0.9). It is noteworthy to mention that the GA concentrations chosen in
the present study were not toxic on normal and cancer cells (Fig. 1B). But GA promotes
Gem activity against cancer cells. Furthermore, our data indicates an inhibitory effect on the
number of colonies, the invasive, and migratory properties of cell lines (Fig. 2–3), in the
presence of the combination treatments in a synergistic manner. A similar reduction of tumor
growth with GA and Gem combination was noticed in a pilot study in xenograft mouse
model (Fig. 8). Such chemosensitization effect of GA observed in our studies concurs with
findings from previous investigation with GA and other chemotherapeutic agents such as
doxorubicin and 5-fluorouracil on ovarian cancer (Wang and Yuan, 2013) and colorectal
respectively (Wei et al., 2017). Altogether, this advice that the Gem concentration required
for its efficient function is reduced enormously with the use of GA as adjuvant in the
treatment. The dose of Gem or number of treatment cycles can be minimized with such
combination treatment regimen.

Author Manuscript

GA has ability to accelerate apoptosis in cancer cells. Previous finding suggests that agents
modulating and promoting G2 phase arrest strengthen the cytotoxicity effect of agents (Xia
et al., 2017). Our cell cycle analysis revealed that the G2 cell population increased in
response to an increase in the dose of GA and induced increased S phase arrest with Gem
combination which acts on DNA (the main mechanism by which Gem causes cell death is
via apoptosis). This suggests our combination strategy inhibited the growth and proliferation
of NSCLC cells by inducing apoptosis via promoting cell cycle arrest (Fig. 5A). This
phenomenon was further proved higher apoptotic population in co-treated cells through
Annexin-V/propidium iodide staining data (Fig. 5B).
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Chemoresistance in cancer cells is often developed by the overexpression of ATP-binding
cassette (ABC) efflux transporters such as the P-glycoprotein (P-gp/ABCB1) (Wang et
al.,2014a). Gem resistance is considered to be consequence of the reduction in drug
concentration in the cancer cells due to either drug efflux or decrease in drug influx (Rudin
et al., 2011; Xue and Liang, 2012). A previous study showed the dependency of reducing Pglycoprotein transport expression for reversing the Gem resistance (Bergman et al., 2003;
Wu et al., 2008). Our data showed that GA and Gem combination treatment increased the Rh
123 accumulation in cancer cells which is an indication for feasibility of higher access to the
drug transport (Fig. 4). This is further confirmed by down-regulation in MDR1/ABCB1
protein (Fig. 7A). Earlier studies proved that GA can enhance the drug intake by suppression
of P-gp efflux activity (Wang et al., 2015). The prime anticancer mechanism of action of
Gem is inhibiting DNA synthesis (Toschi et al., 2005). This is achieved indirectly by
suppressing the ribonucleotide reductase (RR) enzyme activity. RR enzyme converts
ribonucleotide 5’-diphosphates to deoxyribonucleotide 5’-diphosphates, one of the essential
steps in DNA replication (Bergman et al., 2002). Moreover, the RR enzyme is responsible
for cell cycle process regulation (Montano et al., 2017). The high levels of the subunits of
RR expression not only indicate the poor prognosis (Grossi et al., 2015) and Gem resistance
(Achiwa et al., 2004; Jia and Xie, 2015) in lung cancer. Previous studies have shown that
low expression of two subunits of the RR enzyme relates to the sensitivity to Gem (Nakano
et al., 2007). Our co-treatment showed a significant decrease in the expression level of
RRM2 (the catalytic subunit of the RR enzyme). We determined that this synergistical effect
cause is due to intrinsic differences in molecular mechanism and leads to apoptosis
induction and reverse the multi-drug resistance. Gem therapy resistance was observed by
high expression of Bcl-2 associated proteins which is also apoptosis defection. Our study
delineates that GA able to decrease the expression anti-apoptosis proteins such as Bcl-2
indicates possibility to enhance the sensitivity of NSCLC cells to Gem therapy (Fig. 7A).
Further, proteomic profiling further supports elevated levels of apoptosis in cells subjected to
simultaneous co-treatment with both drugs was associated with upregulation of proapoptotic proteins such as Bax, cleaved PARP and cleaved caspase-3 (known key markers
for apoptosis regulation). Similar, previous study done on GA a potent apoptotic inducer,
demonstrated downregulation of Bcl-2 and Bax expression on platinum resistance NSCLC
(Luo et al., 2019).

Author Manuscript

Microarray analysis reports the expression of thousands of genes simultaneously. It can be
used to delineate outperform of GA+Gem combination synergy over their single drug
counterparts. This further confirms the treatment action, either an additive or synergistic.
Our microarray data predicted that A549 cells were indeed very sensitive to the GA+Gem
combination treatments over the single compounds (GA/Gem) (Fig. 7B–E). Through
microarray analysis, we affirmed the combinatorial treatments were influential regulated
over angiogenic, metastatic and ABC family of proteins besides the activation of apoptosis
in NSCLC cells. From the literature and our gene analysis, GA plays a critical role in
combination or adjuvant therapy for reducing the occurrence of NSCLC.
NSCLC can be fatal when it becomes metastatic disease. Angiogenesis is the biological
process that involves development of new blood vessel growth commonly observed in cancer
and metastasis disease. This process also enables the excessive supplementation of necessary
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oxygen and nutrients for growth of cancer cells. Thus, inhibition of such process is clinically
viable treatment options, for example, bevacizumab and ramucirumab. However, these
treatments often associated with severe side effects: hypertension and risk of stroke. Our
treatment strategy indicates an elevated inhibitory effect on endothelial HUVEC cells tube
formation (Fig. 6). A similar observation was made on angiogenesis inhibition effects of GA
(Wan et al., 2019; Yi et al., 2008).
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Various reports presented GA significantly enhances Gem anti-cancer potential in different
ways (Hatami et al., 2020). It may be possible due to bridged cased structure of GA play a
key role to encapsulate amino groups of Gem (Ren et al., 2011) thus deliver Gem in an
efficient manner to cancer cells. Other version is that GA possibly target cancer cells by
various pathways which possibly support such improved Gem activity (Banik et al., 2018).
Therefore, an appropriate ratio of GA and Gem can efficiently serve as combination regimen
for efficiently control the proliferation of tumor cells. However, our future interest of this
combination study is to use a nanoparticle formulation of GA for targeted delivery and
sensitize to Gem chemotherapy (Hatami et al., 2020).
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The prognosis for patients with NSCLC, particularly those with metastasis disease remains
poor. Overall chemotherapy outcome was not satisfactory in NSCLC. Although, Gem
treatments revealed 16–38.5% response rate with 6.6–7.7 months overall survival benefit.
Considering such limited efficacy of this treatment primarily may be due to both intrinsic
and acquired resistance to the therapy and dose-limiting side effects. All these supports
further new efficient adjuvant or drug combination therapies are urgently needed. GA
synergistically promotes therapeutic effects of Gem in multiple in vitro assays. Further, our
results demonstrated GA co-treatment improves the effects of Gem in A549 derived
xenograft tumor mice (Fig. 8). Altogether, this study suggests that GA can act as an adjunct
therapy along with Gem for NSCLC by inhibiting growth, clonogenicity, metastasis,
angiogenesis potential of NSCLC cells (Scheme 1).
Overall, as the concentration GA (2 mg/kg) used in this combinatorial dosage is relatively
low. In many studies, 10-30 mg GA/kg is being used for therapeutic benefit. Besides, GA
has favorable safety and therapeutic profile (Hatami et al., 2020) in lung cancer. We also did
not observe any signs of cytotoxicity due to this combinatorial dosage since we have not
found major weight loss of mice and the vital organs. However, additional studies will
delineate its superior anti-cancer potential of this combination regimen. In the future, we
would consider delineating the role and validation of GA in Gem-resistance cell line and
tumor mice models. Together, these results promote possibility to implement GA as an
adjuvant treatment module to improve the therapeutic benefit of Gem in NSCLC patients.
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5.

Conclusion
This study reports a new therapeutic regimen based on a combination of a natural compound
and Gem. GA and Gem combination treatment demonstrated synergistic anti-tumor effects
through various functional assays in NSCLC cells. Our results confirmed that GA has
potential to potentiate Gem-induced cell cycle arrest and cellular apoptosis. Co-treatment
strategy enhanced the anti-tumor effects of Gem by downregulating MDR1, RRM1, and
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anti-apoptosis protein (Bcl-2) and upregulation of apoptosis proteins (Bax) expression.
Importantly, in vivo evaluation in xenograft tumor mouse model revealed enhanced
efficiency of Gem by GA co-treatment. Overall, this study suggests that GA can act as an
adjunct therapy along with Gem for NSCLC. Further investigations are warranted in large
scale animal models to establish this as an efficient combination regimen for NSCLC.
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Fig. 1. The synergistic inhibitory effect of GA and Gem combination on the cell viability of
NSCLC cells.

(A) Chemical structure of GA and Gem. (B-E) Cell viability was assessed by MTT assay
and IC50 was calculated. (B) A549 and H1299 NSCLC cell lines and were incubated with
different concentration of GA, (C) lung epithelial (BEAS-2B) was incubated with GA and
Gem for 48 h, (D-E) A549 and H1299 cell lines were incubated with GA and Gem
combination and Gem alone for 48 h. (F) Heat map of combination index using Chou and
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Talalay method for different concentration ratio of GA and Gem on A549 and H1299
NSCLC. Values represent the mean ± S.E.M. (n =3).
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Fig. 2. The significant inhibitory effect of GA and Gem combination on the colony formation of
NSCLC cells.

(A) Colony formation capability of NSCLC cells were analyzed for the above-mentioned
individual GA and Gem concentration, and their combination for 15 days. (B) Graphical
representation of quantitative data analyzed with ImageJ; untreated cells were taken as
control (100%). Values represent the mean ± S.E.M. (n=3). The significance level was *P <
0.05 and **P < 0.01 compared to controls cells, and #P < 0.05 compared to their individual
drugs.
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Fig. 3. GA and Gem combination significantly inhibited cell migration and invasion abilities.

(A-B) Migration ability was analyzed using a Transwell assay, migration cell images and
graphical representation of quantitative data showing the number of migrated cells. (C-D)
The cell invasion abilities were analyzed using a Boyden chamber assay, invasion cell
images and graphical representation of quantitative data showing the number of invaded
cells. Both the data were analyzed by ImageJ software. Values represent the mean ± S.E.M.
(n = 3). The significance level was *P < 0.05 and **P < 0.01 compared to controls cells, and
#P < 0.05 compared to their individual drugs.
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Fig. 4. Effect of GA on intracellular Rh123 accumulation in A549 and H1299 cells.

(A) Cells were incubated with medium containing 2.62 mM Rh123 pretreated with GA and
Gem with the respective combination dosage for 24 h and without pretreatment. After 30
min, mean fluorescent intensity (MFI) associated with intracellular Rh123 accumulation was
assessed. Representative images were presented. (B) A graphical representation of
quantitative data analyzed by flow cytometry. Values represent the mean ± S.E.M. (n = 3).
The significance level was *P < 0.05 and *P < 0.01 compared to controls cells, and #P <
0.05 compared to GA and Gem.
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Fig. 5. Effect of GA and Gem combination on cell cycle and apoptosis induction in NSCLC.

(A) GA and Gem combination increased the apoptosis population on A549 cells, after 24 hr
treatment incubation for cell cycle analysis. (B) A549 and H1299 cells were incubated with
GA and Gem and respective combination concentrations of GA+Gem for 48 h. The X-axis
shows Annexin V-FITC staining and Y-axis indicates Propidium iodide staining; Lower left
(LL) quadrant: viable cells; lower right (LR) quadrant: early apoptotic cells; upper left (UL)
quadrant: necrotic cells, upper right (UR) quadrant: late apoptotic cells. Data representative
of triplicate (n = 3).
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Fig. 6. Inhibition of tube formation by GA and Gem combination.

HUVEC cells were treated with GA, Gem, and their combination for 4 h and total master
segments lengths were measured with ImageJ. (A) Representative images of HUVEC cell
line treated and untreated (control). Magnification = 10× (scale bar = 500 μm). (B) Results
of three replicates are shown as the mean master segments length (Unit: Pixels) compared to
the control. Values represent the mean ± S.E.M. (n =3); *P < 0.05, **P < 0.01, and ***P <
0.001 treatments compared to control groups and #P < 0.05 combination treatment compared
to GA and Gem treatments.
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Fig. 7. Molecular effects of combination treatment.

(A) Western blot analysis confirms the significant induction of apoptotic signaling proteins
after the treatment with GA+Gem compare to alone drugs and control. Protein extractions
from A549 cells treated with different concentrations of 200 nM GA and 200 nM Gem, and
equivalent combination of these two agents, cl-PARP and cl-caspase 3 indicates cleaved
PARP and cleaved caspase 3, respectively, β-actin was probed for as internal equal protein
control. (B-E) Heap map analysis of the differential expression of genes in A549 cells after
the GA, Gem and GA+Gem treatments. (B) Apoptotic signaling, (C) ABC family/Nuclear
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translocation signaling, (D) EMT signaling, and (E) Angiogenic signaling. Data represented
from triplicates.
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Fig. 8. GA+Gem combination treatment significantly induce anticancer efficacy in A549 tumor
xenografts.

Author Manuscript

(A) Representative images of A549 tumor bearing male mice treated with control vehicle
(no therapy), GA (2 mg/kg mice), Gem (20 mg/kg mice), and GA+Gem (2+20 mg/kg mice),
respectively. Treatments were given twice a week for 3-4 weeks. Arrow represents starting
of administration time. (B) Graphical representation of tumor volumes (mm3) as a function
of time in control, GA, Gem, and GA+Gem treatments mice bearing A549 NSCLC tumors.
Values represent the mean ± S.E.M. (n =3); The significance level was *P < 0.05 and **P <
0.01 compared to controls cells, and #P < 0.05 compared to GA and Gem. (C)
Representative tumor images of treatment groups indicating apparent change in angiogenic
blood vessels with combination treatment. (D) Immunohistochemistry images of mice
tumors upon treatment. A greater reduction of PCNA staining in GA+Gem indicate cancer
cell proliferation inhibition.
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Scheme 1.

Schematic representation of adjuvant therapy of GA for enhancing Gem therapy in NSCLC.
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Summary of cell cycle distribution of A549 cells.
Cell cycle

Ctrl

GA 100

GA 200

Gem 200

GA 100+Gem 200

GA 100+Gem 200

G0 / G1

60.32±1.32

21.84 ± 0.65

43.25 ± 1.32

33.26 ± 0.98

—

—

G2

11.34 ± 1.56

32.01 ± 0.30

16.01 ± 0.85

0.15 ± 1.62

—

—

S

26.87 ± 0.88

45.62 ± 1.01

41.32 ± 1.32

65.32 ± 1.03

—

—

—

—

—

—

15.22 ± 0.65

26.09 ± 0.74

Apoptosis

Author Manuscript
Author Manuscript
Author Manuscript
Eur J Pharmacol. Author manuscript; available in PMC 2021 December 05.

Hatami et al.

Page 31

Table 2.

Author Manuscript

Summary of cell death analysis (Annexin V-PI) of A549 and H1299 cells.
A549
Treatments

H1299

Ctrl

GA

Gem

GA+Gem

Ctrl

GA

Gem

GA+Gem

Live Cells

98.3±0.3

95.9±0.4

88.5±0.05

68.1±0.6

98.1±0.5

95.9±1.0

87.6±0.9

68.4±1.0

Annexin V

1.0±0.1

1.4±0.2

3.9±1.0

5.8±0.6

0.8±1.0

1.5±0.4

5.0 ±0.3

7.4±0.5

PI

0.9±0.3

0.7±0.9

3.6±0.6

5.5±0.1

0.4±0.3

0.7±0.2

4.1±0.8

6.1±0.1

Annexin V + PI

0.4±0.1

0.7±0.3

3.1±0.9

19.3±1.0

0.7±1.1

0.7±0.1

4.2±0.3

19.0±1.1
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